Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

TB Still a Major International Killer

By Drug Discovery Trends Editor | March 29, 2016

Dr Nick West. Source: University of QueenslandTuberculosis: Many Australians believe it was eradicated years ago – but the grim reality is that TB is still a major world-wide killer, responsible for 1.5 million deaths a year.

Today is World Tuberculosis Day, but every day is TB day for University of Queensland researcher Dr Nick West, as he battles to combat a disease that kills someone every 21 seconds.

“A lot of people think TB was only a problem when their grandparents were young but, sadly, that couldn’t be further from the truth,” Dr West said.

“Despite a concerted international effort, there were 9.6 million new cases of TB in 2014, resulting in 1.5 million deaths. And one in three people globally is infected with TB.

Dr West, the founder and Laboratory Head of the Tuberculosis Research Laboratory in UQ’s School of Chemistry and Molecular Biosciences, said TB, caused by the bacteria Mycobacterium tuberculosis, was highly contagious and could be spread from person to person simply by breathing.

“When a person sick with TB coughs or sneezes, little droplets containing the bacteria can float through the air, allowing them to be easily inhaled by others,” Dr West said.

He said intensified research efforts have resulted in new vaccine strategies, new candidate antibiotics and rapid diagnostics that suggest that one of the oldest human infections could be beaten.

“Any successful anti-TB strategy has three pillars – prevention, diagnosis and treatment,” Dr West said.

“My team and I are contributing to all three areas, using modern genomic technologies to gain a better understanding of how bacteria actually cause TB.

“In the past few years we’ve made huge progress in this area.

“We’re now in the process of translating our discoveries into practical solutions such as new therapies and control measures.”

Source: University of Queensland


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE